ACM
NBIX icon

ADAR1 Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

ADAR1 Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,500
Closed -$329K – 323
2026
Q1 		$329K Buy
+2,500
New +$332K 0.02% 230

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management's NBIX Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2,500 shares — an estimated $329K sold.

ADAR1 Capital Management first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $329K in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 2,500 Neurocrine Biosciences shares in Q2 2026, an estimated $329K.
  • ADAR1 Capital Management first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
  • ADAR1 Capital Management's Neurocrine Biosciences position peaked at $329K in Q1 2026.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.